Clinical Trial Update: Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and tolerability of an intravenous dose of MEDI-546 in Japanese patients with systemic lupus erythematosus has completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• MEDI-546

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: COMPLETED | Results posted: 2019-03-13